Longevipedia
Therapeutic Plasma Exchange
Medical procedure for plasma replacement therapy
PAGE CONTENTS
Therapeutic Plasma Exchange (TPE)
Overview
Benefits (evidence graded)
Drawbacks & uncertainties
How it works (mechanism)
Dosage information / protocol
Safety information (summary)
Side effects
Precautions
Evidence database (core)
FAQs
See also
References

Therapeutic Plasma Exchange (TPE)

Therapeutic plasma exchange (TPE) removes a patient’s plasma and replaces it with an appropriate fluid (usually 5% albumin or plasma) using centrifugal or membrane-based separation.[1][2] It is an established therapy for selected antibody- or toxin-mediated diseases (e.g., thrombotic thrombocytopenic purpura, myasthenia gravis) and is being explored for age-related applications. Evidence for longevity/biological-age modification in humans remains limited and investigational.[1:1][3][4]

Therapeutic plasma exchange medical procedure

Overview

  • What it is: Extracorporeal removal of plasma with replacement fluid to eliminate pathogenic circulating factors.[1:2][2:1]
  • Typical clinical use: Autoimmune/antibody-mediated and toxin-mediated disorders per ASFA guidelines.[1:3]
  • Longevity bottom line: Preclinical work supports dilution/removal of inhibitory plasma factors; human data for epigenetic-age or lifespan effects are insufficient; use outside approved indications should occur only in trials.[3:1][5]

Benefits (evidence graded)

  • Autoantibody/toxin burden — ↓ large — Rapid Ig/complement removal — A (indication-dependent).[1:4][2:2]
  • Alzheimer’s disease (AD) symptoms — ↓ decline small-to-moderate — AMBAR albumin/TPE regimen signals in subsets; requires replication — C.[6][7]
  • Inflammatory cytokines — ↓ small-to-moderate — Heterogeneous; transient — C.[8][9]
  • Lipids/Lp(a) (with apheresis variants) — ↓ moderate-to-large — Technique-specific — B.[10]
  • Biological/epigenetic age — Insufficient evidence for effect — F.[3:2][5:1]

Grading rubric: A (multiple high-quality meta-analyses of RCTs); B (several RCTs; generally consistent); C (small/heterogeneous RCTs or observational; mixed); D (limited/low-quality or conflicting); E (preliminary/animal/mechanistic); F (no effect or harm with high-quality evidence).

Drawbacks & uncertainties

  • Longevity claims: No peer-reviewed RCT evidence that TPE lowers epigenetic age in humans; preclinical plasma dilution data cannot be assumed to translate.[3:3][5:2]
  • Heterogeneous protocols: Volume, frequency, anticoagulant, and replacement vary and affect outcomes.[1:5][11]
  • Transience: Removed factors can rebound; durable disease or biomarker changes may require repeated courses.[1:6][11:1]
  • Risks: Citrate-related hypocalcemia, hypotension, allergic reactions (plasma), catheter complications; rare serious adverse events (SAEs).[4:1][12]

How it works (mechanism)

  • Bulk removal of circulating factors (IgG/IgM, immune complexes, complement, cytokines), reducing pathogenic signaling.[2:3][13]
  • Alters proteome/exposome: Replacement fluid (albumin/plasma) changes binding, oncotic pressure, and transport of mediators.[2:4]
  • Kinetics: One plasma volume (PV) exchange removes ~60–70% of intravascular constituents; repeated sessions increase cumulative removal.[11:2]
  • Preclinical “neutral blood exchange”: Dilution with saline/albumin in old mice reduces inhibitory factors and improves tissue repair/function.[3:4]
  • Immune modulation: Indirect effects on B-cell/autoantibody dynamics and complement activity.[2:5]

Dosage information / protocol

  • Standard range: 1.0–1.5 PV per session; 5% albumin replacement for most indications; plasma for specific needs (e.g., TTP for ADAMTS13).[1:7][11:3]
  • Anticoagulant: Citrate (ACD-A) commonly; monitor ionized calcium; supplement calcium as needed.[4:2][12:1]
  • Frequency: Typically 3–5 sessions over 1–2 weeks for many immune indications; maintenance per disease course. Experimental longevity/AD regimens used repeated low-volume exchanges with albumin ± IVIG.[6:1][7:1]
  • Access: Peripheral or central venous catheter depending on veins/flow.[1:8]

Dosage at a glance

Use case Typical dose/volume Timing Notes
Antibody-mediated disease 1.0–1.5 PV per session Every 24–48 h (3–5 sessions) 5% albumin replacement; adjust per labs[1:9][11:4]
Hyperviscosity 1.0 PV Single or repeated as needed Consider plasma if coagulopathy present[1:10]
Alzheimer’s (experimental) Low-volume exchanges Weekly→monthly per protocol Albumin replacement ± IVIG; investigational[6:2][7:2]

Safety information (summary)

Common: Peri-procedural paresthesias (citrate), cramps, hypotension, flushing/urticaria (plasma), access-site issues. Avoid in unstable hemodynamics; use plasma when coagulation factors required. Monitor ionized calcium, CBC, fibrinogen, electrolytes; consider infection risk with central access.[1:11][4:3][12:2]

Side effects

Effect Frequency/notes Route Evidence
Citrate hypocalcemia (paresthesia, tetany) Common; dose-related; mitigated by calcium Extracorporeal (citrate) Probable[4:4][12:3]
Hypotension/vasovagal Occasional; volume/vasomotor related Systemic Probable[4:5]
Allergic/urticarial reaction Occasional; higher with plasma replacement Systemic Probable[4:6]
Catheter-related infection/thrombosis Infrequent; access-dependent Vascular access Probable[4:7]
Bleeding (low fibrinogen) Infrequent; monitor fibrinogen, use plasma if needed Systemic Possible[1:12][11:5]
Serious adverse events Rare (<1%); anaphylaxis, severe hypotension Systemic Probable[4:8]

Precautions

Population/condition Precaution What to monitor
Severe heart failure/unstable hemodynamics Risk of decompensation BP, volume status
Hypocalcemia risk (low vitamin D, CKD) Citrate toxicity Ionized calcium, symptoms
Anticoagulation/coagulopathy Bleeding with albumin-only replacement Fibrinogen, INR, aPTT
Infection risk/central line Catheter sepsis/thrombosis Line care, CBC, cultures if febrile
Allergy to plasma products Hypersensitivity Premedication, consider albumin replacement

Evidence database (core)

Outcome Direction Effect size (units) # Studies # Participants Evidence grade Notes
Autoantibody levels Small Decrease Large (% reduction after 1–3 sessions) Multiple RCTs/series (indication-specific) Hundreds A Rapid intravascular Ig removal[1:13][2:6][11:6]
AD cognitive decline (AMBAR) Small Decrease Small–moderate slope change 1 RCT (multicenter) + extensions ~300–350 C Signal in moderate AD; replication pending[6:3][7:3]
Cytokines (IL-6, TNF-α) Small Decrease Small Small RCTs/observational <200 C Transient; protocol-dependent[8:1][9:1]
Lipoprotein(a) (apheresis variants) Small Decrease Moderate–large Multiple trials Hundreds B Technique-specific; not standard TPE[10:1]
Epigenetic age — Insufficient data 0 RCTs — F No peer-reviewed RCT evidence in humans[3:5][5:3]

FAQs

  • Does TPE reverse biological (epigenetic) age?

    • No confirmed human RCT evidence. Preclinical dilution studies in mice improved tissue function, but translation is unproven.[3:6]

  • How long do effects last?

    • Removed factors can rebound; durability depends on disease biology and session frequency.[1:14][11:7]

  • Can albumin alone (without full plasma exchange) help AD?

    • AMBAR combined low-volume exchanges with albumin replacement (± IVIG) and reported signals in moderate AD; confirmatory trials are needed.[6:4][7:4]

  • Who should avoid TPE for “anti-aging”?

    • Healthy individuals outside clinical trials; FDA has warned against plasma infusions marketed for anti-aging.[5:4]

See also

References

  1. ASFA Apheresis Committee. Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach (2023 update). J Clin Apher. 2023;38(Suppl). PubMed: https://pubmed.ncbi.nlm.nih.gov/37017433/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

  2. Reeves HM, Winters JL. The mechanisms of action of plasma exchange. Br J Haematol. 2014;164(3):342–351. PubMed: https://pubmed.ncbi.nlm.nih.gov/24172059/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

  3. Mehdipour M, et al. Rejuvenation of three germ layers tissues by exchanging old blood plasma with saline-albumin. Aging (Albany NY). 2020;12(11):8790–8819. PubMed: https://pubmed.ncbi.nlm.nih.gov/32474458/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

  4. Winters JL. Complications of therapeutic plasma exchange. Transfusion. 2011;51(8):1781–1801. PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Winters+complications+therapeutic+plasma+exchange ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

  5. U.S. FDA. FDA warns against receiving young donor plasma infusions that are promoted as unproven treatments. 2019. FDA: https://www.fda.gov/news-events/press-announcements/fda-warns-against-receiving-young-donor-plasma-infusions ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

  6. Boada M, et al. A randomized clinical trial of plasma exchange with albumin replacement (AMBAR) in Alzheimer’s disease. Alzheimers Dement. 2020;16:1412–1425. PubMed: https://pubmed.ncbi.nlm.nih.gov/32715623/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

  7. Boada M, et al. Albumin replacement therapy in Alzheimer’s disease: phase II results and post hoc analyses. J Alzheimers Dis. 2017;56(2): . PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Boada+albumin+replacement+Alzheimer's+2017 ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

  8. Stahl K, Busch M, et al. Therapeutic plasma exchange in sepsis and systemic inflammation: a systematic review. Crit Care. 2020;24:278. PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=therapeutic+plasma+exchange+sepsis+systematic+review+2020 ↩︎ ↩︎

  9. Busund R, et al. Plasma exchange in severe sepsis and septic shock: a prospective, randomized, controlled trial. Intensive Care Med. 2002;28(10):1434–1439. PubMed: https://pubmed.ncbi.nlm.nih.gov/12373468/ ↩︎ ↩︎

  10. Roeseler E, et al. Long-term effects of lipoprotein apheresis on Lp(a) levels and cardiovascular outcomes. Eur J Clin Invest. 2014;44(10): . PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=lipoprotein+apheresis+long-term+Lp(a)+outcomes ↩︎ ↩︎

  11. Kaplan AA. Therapeutic plasma exchange: core curriculum. Am J Kidney Dis. 2013;61(3):371–380. PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Kaplan+Therapeutic+plasma+exchange+core+curriculum+2013 ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎

  12. Mokrzycki MH, Balogun RA. Therapeutic apheresis: a review of complications and management. Transfus Apher Sci. 2011;45(3):160–167. PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Mokrzycki+Balogun+apheresis+complications+2011 ↩︎ ↩︎ ↩︎ ↩︎

  13. Szczepiorkowski ZM, et al. Guidelines and principles for therapeutic apheresis—ASFA. J Clin Apher. 2010;25(3):83–177. PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Szczepiorkowski+therapeutic+apheresis+guidelines+2010 ↩︎

Comments

Discussion

Privacy PolicyTerms of UseMedical Disclaimer

The information provided on Longevidence is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before starting any new diet, exercise, supplement, or medical protocol.

Longevipedia 2026